<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01232140</url>
  </required_header>
  <id_info>
    <org_study_id>CATCH study</org_study_id>
    <secondary_id>AECOPD</secondary_id>
    <nct_id>NCT01232140</nct_id>
  </id_info>
  <brief_title>CRP-guided Antibiotic Treatment in COPD Exacerbations Admitted to the Hospital</brief_title>
  <acronym>CATCH</acronym>
  <official_title>CRP-guided Antibiotic Treatment in Patients Hospitalized With Acute Exacerbations of COPD Patients. A Randomized Controlled Intervention Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Center Alkmaar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical Center Alkmaar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Acute exacerbations are key events in chronic obstructive pulmonary disease
      (COPD), resulting in poorer quality of life. Causes include irritants, viruses and bacterial
      pathogens. These exacerbations are often treated with a combination of corticosteroids,
      bronchodilators and antibiotics, but the benefit of antibiotic therapy remains controversial.
      Several trials studying antibiotic treatment in AECOPD showed conflicting data, with several
      large studies failing to demonstrate superiority of antibiotic therapy over placebo. Other
      trials indicated that antibiotic therapy is effective in patients who have at least two of
      the following symptoms: increased dyspnoea, increased sputum volume and increased sputum
      purulence. Ever since sputum purulence has been used as a predictive marker in AECOPD, a
      strategy that has been integrated in the GOLD guideline for treatment of AECOPD. However, the
      color of sputum reported by patients is not always reliable and inspection of sputum is not
      always possible. Several serum biomarkers such as C-reactive protein (CRP) and procalcitonin
      (PCT) are now available. In a recent trial of doxycycline in addition to systemic
      corticosteroids for patients hospitalized with AECOPD we found that CRP might be valuable as
      a marker predictive of response to antibiotic treatment in AECOPD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: CRP-guided antibiotic therapy will be compared with standard antibiotic therapy in
      AECOPD. Our aim is that CRP guided therapy will lead to 20% reduction in antibiotic
      consumption.

      Study design: randomized controlled intervention trial Study population: Hospitalised COPD
      patients with acute exacerbation. Intervention (if applicable): Patients with type 1 and 2
      exacerbation will be assigned to either CRP guided therapy or antibiotic therapy according to
      GOLD guidelines.

      Main study parameters/endpoints: The main endpoint of the study is the reduction in
      antibiotic consumption. Furthermore, the real incidence of infiltrates in AECOPD with fever
      will be studied. As secondary outcome the objectives length of hospitalization, time to
      treatment failure within 30-days and time to next exacerbation will be assessed. The relation
      between the level of biomarkers the presence of infiltrates on the HRCT will be investigated.

      Subjective improvement in symptoms will be measured by symptoms (VAS-LRTI) and quality of
      life will be assessed by St George's Respiratory Questionnaire. Finally, adverse effects of
      the antibiotic treatment will be recorded.

      In order to observe a significant difference of antibiotic consumption, 60% in standard
      antibiotic group and 40% in CRP guided antibiotic group, with a power of 0.8, a total of 110
      patients have to be assigned by randomisation to each group.

      Nature and extent of the burden and risks associated with participation, benefit and group
      relatedness: Patients in both treatment arms will receive a non-experimental treatment. Both
      treatment options are recognized as part of standard care. The burden associated with
      participation is limited to a total of 3 visits to the hospital and phone call for data
      assessment at regular follow-up. There are no specific risks involved in participating. Less
      adverse effects may be beneficially for the patient.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients treated with antibiotics during hospital stay</measure>
    <time_frame>10 days</time_frame>
    <description>Sputum purulence has been used as a predictive marker in AECOPD.However, the color of sputum reported by patients is not always reliable and inspection of sputum is not always possible. Serum biomarker such as C-reactive protein (CRP) represents systemic inflammation.In the present study, we will compare CRP guided antibiotic treatment versus treatment according to GOLD strategy. Our hyposthesis is that CRP-guided therapy results in lower number of antibiotic prescriptions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure within 30-days</measure>
    <time_frame>30 days</time_frame>
    <description>Treatment failure within 30 days after hospital admission will be compared</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>30 days</time_frame>
    <description>Length of hospital stay for the exacerbation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next exacerbation</measure>
    <time_frame>1 year</time_frame>
    <description>Time to the next exacerbation with a follow-up period of one year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom scores (VAS-LRTI, George's Respiratory Questionnaire)</measure>
    <time_frame>30 days</time_frame>
    <description>Symptom score (VAS-LRTI) and Quality of life (George's Respiratory Questionnaire) will be measured at onset and recovery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>30 days</time_frame>
    <description>Adverse events of antibiotic treatment are recorded during follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>COPD</condition>
  <condition>Exacerbation</condition>
  <condition>Bronchitis</condition>
  <condition>Sputum</condition>
  <condition>C-Reactive Protein</condition>
  <arm_group>
    <arm_group_label>CRP-guided antibiotic treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If CRP&gt; 50 mg/l a patient receive antibiotic treatment, whereas in those patients with CRP =&lt; 50 mg/l antibiotic treatment is withheld.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GOLD strategy-antibiotic treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>According to the GOLD strategy a patient with an AECOPD should prescribed antibiotic treatment if a patient has symptoms of increased dyspnea, increased sputum production and change of sputum color. Two of these three criteria should be present, however change in sputum production is obligatory.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CRP-guided antibiotic treatment</intervention_name>
    <description>If CRP&gt; 50 mg/l patients with AECOPD receive antibiotic treatment, whereas in those patients with CRP =&lt; 50 mg/l antibiotic treatment are withheld. This will be compared to the regular antibiotic treatment that has been advised by the GOLD strategy</description>
    <arm_group_label>CRP-guided antibiotic treatment</arm_group_label>
    <arm_group_label>GOLD strategy-antibiotic treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 40 or over. No upper age limit will be employed.

          -  Written informed consent obtained.

          -  AECOPD according to the GOLD guideline. An exacerbation of COPD is defined as an event
             in the natural course of the disease characterized by a change in the patient's
             baseline dyspnoea, cough, and/or sputum that is beyond normal day-to-day variations,
             is acute in onset, and may warrant a change in regular medication in a patient with
             underlying COPD.

          -  Criteria for hospital admission according to the GOLD: marked increase in symptoms
             (i.e. resting dyspnoea), severe underlying COPD, onset of new physical signs
             (cyanosis, edema), failure to respond to initial medical management, significant co
             morbidities, frequent exacerbations, newly occurring arrhythmias, diagnostic
             uncertainty.

          -  Former of current smoker with a minimum smoking history of 10 pack years.

          -  Patients have to be capable of ingesting oral medication.

          -  Patients have to be mentally capable of participating in the study (able to complete
             questionnaires and perform lung function tests).

          -  Life expectancy â‰¥ 30 days.

        Exclusion Criteria:

          -  Pregnant or lactating women, or women of childbearing age not using an acceptable
             method of contraception.

          -  Pretreatment with corticosteroids (cumulative dose &gt;210 mg) for the present
             exacerbation.

          -  Progression or new radiographic abnormalities on the chest X-ray or CT scan compatible
             with pneumonia.

          -  bronchiectasis (HRCT confirmed).

          -  Cystic fibrosis.

          -  Tuberculosis.

          -  Immunodeficiency disorders such as AIDS, humoral immune defect, ciliary dysfunction
             etc., and the use of immunosuppressive drugs (&gt;30 mg prednisolone/day maintenance dose
             or equivalent for more than 4 weeks).

          -  Recent or unresolved lung malignancy.

          -  Other disease likely to require antibiotic therapy, such as recurrent sinusitis or
             urinary tract infection.

          -  Significant gastrointestinal or other conditions that may affect study drug
             absorption.

          -  Class III or IV congestive heart failure or stroke.

          -  Newly diagnosed pulmonary embolism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>W.G. Boersma, PHD,MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical Centre Alkmaar</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>W.G.Boersma</name>
      <address>
        <city>Alkmaar</city>
        <state>Noord-Holland</state>
        <zip>1829JC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>W.G. Boersma, PHD,MD</last_name>
      <phone>0031-725482750</phone>
      <email>w.boersma@mca.nl</email>
    </contact>
    <contact_backup>
      <last_name>J.M.A. Daniels, PHD, MD</last_name>
      <phone>0031204444444</phone>
      <email>j.daniels@vumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>W.G. Boersma, PHD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>J.M.A. Daniels, PHD,MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>C.S. de Graaff, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Daniels JM, Snijders D, de Graaff CS, Vlaspolder F, Jansen HM, Boersma WG. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010 Jan 15;181(2):150-7. doi: 10.1164/rccm.200906-0837OC. Epub 2009 Oct 29.</citation>
    <PMID>19875685</PMID>
  </results_reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2010</study_first_submitted>
  <study_first_submitted_qc>November 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2010</study_first_posted>
  <last_update_submitted>March 21, 2012</last_update_submitted>
  <last_update_submitted_qc>March 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical Center Alkmaar</investigator_affiliation>
    <investigator_full_name>W.G.Boersma</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>exacerbation</keyword>
  <keyword>antibiotic treatment</keyword>
  <keyword>CRP</keyword>
  <keyword>sputum</keyword>
  <keyword>inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

